Accessibility Menu
Arrow-Thin-Down
S&P 500
6,735.35
+0.0%
+0.22
Arrow-Thin-Down
DJI
46,924.74
+0.5%
+218.16
Arrow-Thin-Down
NASDAQ
22,953.67
-0.2%
-36.88
Arrow-Thin-Down
Bitcoin
$110,786
+0.1%
+$73.68
Arrow-Thin-Down
AAPL
$263.1
+0.3%
+$0.86
Arrow-Thin-Down
AMZN
$222.2
+2.6%
+$5.72
Arrow-Thin-Down
GOOG
$251.47
-2.2%
-$5.55
Arrow-Thin-Down
META
$733.27
+0.1%
+$1.1
Arrow-Thin-Down
MSFT
$518.06
+0.2%
+$1.27
Arrow-Thin-Down
NVDA
$181.16
-0.8%
-$1.48
Arrow-Thin-Down
TSLA
$442.6
-1.1%
-$4.83
Daily Stock GainersDaily Stock LosersMost Active Stocks
Armata Pharmaceuticals Stock Quote

Armata Pharmaceuticals (NYSEMKT: ARMP)

$3.47
(-0.1%)
-0.01
Price as of October 21, 2025, 3:59 p.m. ET

KEY DATA POINTS

Current Price
$3.47
Daily Change
(-0.1%) $0.01
Day's Range
$3.45 - $3.5
Previous Close
$3.47
Open
$3.49
Beta
0.42
Volume
10,953
Average Volume
10,176
Sector
Health Care
Market Cap
125.9M
Market Cap / Employee
$3.48M
52wk Range
$0.9 - $3.5
Revenue
-
Gross Margin
0.79%
Dividend Yield
N/A
EPS
-$0.74
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Armata Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ARMP+47.08%+0.58%+0.12%-25%
S&P+14.84%+96.04%+14.41%+134%

Armata Pharmaceuticals Company Info

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.

News & Analysis

Featured Article

Armata Posts 59 Percent Q2 Revenue Jump

Motley Fool Markets Team  |  Aug 12, 2025

Financial Health

General

Q2 2025YOY Change
Revenue$2.17M0.0%
Gross Profit$1.80M672.4%
Gross Margin83.13%0.0%
Market Cap$68.77M-30.8%
Market Cap / Employee$1.15M0.0%
Employees60-9.1%
Net Income-$16.30M-281.3%
EBITDA-$6.48M44.2%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$4.33M-83.6%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$27.13M-3.6%
Short Term Debt$116.82M-1.0%

Ratios

Q2 2025YOY Change
Return On Assets-27.19%36.8%
Return On Invested Capital-61.57%13.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$7.36M36.2%
Operating Free Cash Flow-$7.21M29.1%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-1.86-1.31-1.10-1.28-27.28%
Price to Sales15.6821.1311.2410.01-76.75%
Price to Tangible Book Value-1.43-1.03-0.86-1.02-28.00%
Enterprise Value to EBITDA-22.10-22.30-22.50-32.1733.30%
Return on Equity-3439.4%-
Total Debt$140.33M$126.52M$134.66M$143.96M-1.50%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services